TransCode Therapeutics Advances RNA Cancer Therapy in Phase 1a Trial, Shows Promising Early Results
TransCode Therapeutics reports encouraging progress in its Phase 1a trial of TTX-MC138, an RNA-based cancer therapy targeting microRNA-10b, with initial data suggesting potential effectiveness in treating metastatic tumors.
TransCode Therapeutics has reported significant progress in its Phase 1a clinical trial of TTX-MC138, an innovative RNA-based therapeutic targeting microRNA-10b in metastatic cancer patients. The study has enrolled thirteen patients across four dosing levels, with eight patients continuing in the trial.
Preliminary data from the trial reveal promising early indicators of therapeutic potential. Two patients have demonstrated stable disease after seven months, and no significant toxicities have been observed during the initial testing phase. Early pharmacokinetic and pharmacodynamic data suggest target engagement and a dose-response relationship consistent with preclinical findings.
The results are particularly noteworthy for potential advancements in metastatic cancer treatment. By targeting microRNA-10b, a well-documented biomarker of metastasis, TTX-MC138 represents a novel approach to addressing challenging cancer progression. The company's proprietary nanoparticle platform enables more effective RNA delivery, potentially overcoming previous limitations in RNA therapeutic development.
These initial findings support TransCode's plan to advance the trial to Phase 1b, where researchers will conduct expanded evaluations of safety and anti-tumor activity. The results could represent a significant step forward in developing targeted therapies for patients with metastatic cancers that currently have limited treatment options.